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Objective: To evaluate the association between serum concentrations of complement factor-3 (C3)
with anthropometric, biochemical, and lifestyle features in healthy young adults.
Methods: From 157 young healthy adults 18 to 35 y old, anthropometric measurements and body
composition, systolic and diastolic blood pressures, and lifestyle data were collected and analyzed.
Blood samples were collected after a 12-h fast for the determination of glucose, triacylglycerols,
total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, insulin,
C3, ceruloplasmin, and uric acid.
Results: Complement factor-3 correlated directly with body mass index (r ¼ 0.23417, P ¼ 0.0032),
body fat mass (bioelectrical impedance analysis; r ¼ 0.33407, P < 0.0001), percentage of body fat
(bioelectrical impedance analysis; r ¼ 0.26873, P ¼ 0.0007), waist circumference (r ¼ 0.21266, P ¼
0.0075), insulin (r ¼ 0.26152, P ¼ 0.0009), homeostasis model assessment of insulin resistance (r ¼
0.24831, P ¼ 0.0017), total cholesterol (r ¼ 0.23335, P ¼ 0.0033), triacylglycerols (r ¼ 0.38435,
P < 0.0001), and other outcome measurements. In the multiple linear regression analysis, tri-
acylglycerols (r2 ¼ 0.1379, P < 0.0001) and body fat mass (bioelectrical impedance analysis; r2 ¼
0.0621, P ¼ 0.0010) were independently associated with the C3 concentration after adjusting for
age, gender, smoking status, and physical activity.
Conclusion: Complement factor-3 seems to be related to several anthropometric and biochemical
measurements in healthy young adults. These results demonstrate an independent role of tri-
acylglycerols, a component of the metabolic syndrome, and body fat mass as possible predictors of
C3 concentrations. Thus, C3 can be used as an early marker for metabolic syndrome manifestations.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Adipose tissue is an active endocrine organ that secretes
several factors called adipokines, such as complement factor-3
(C3), which play a role in some inﬂammatory manifestations
associated with obesity and the metabolic syndrome (MS) [1,2].
The third component of the complement system, C3, is
a multifunctional protein because it plays a central role in the
activation of three pathways of the complement system (classic,the Coordination for the
f Education of Brazil and
inas Gerais proposal (CDS
ax: þ55-313-899-2541.
sevier OA license.alternative, and lectin pathways) [3,4]. C3 is an adipokine
produced primarily by the liver [5], but adipose tissue [3] and
activatedmacrophages also produce themolecule [6]. In addition
to its role in exercise and many important immune system
functions, C3 behaves like an acute-phase protein and is
synthesized by hepatocytes in response to interleukin-1b, which
is secreted by activated macrophages [3,7] at the site of inﬂam-
mation. In this context, C3 has been studied because of its
expression and secretion by adipose tissue [3].
An increase in C3 concentrations is associated with increases
in fasting plasma glucose, triacylglycerol concentrations [8],
insulin resistance (IR) [9], body mass index (BMI), waist
circumference (WC), body fat [8], and bodyweight gain [9]. Thus,
these results suggest that C3 may be a risk factor for developing
type 2 diabetes [10] and obesity [9] and a risk indicator for
coronary heart disease [11]. Nevertheless, in addition to the MS
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with components of MS [12] and conferring their risk for
cardiovascular disease [12].
Besides the association between anthropometric measure-
ments and body composition with inﬂammation, several risk
factors related to lifestyle have been associated with inﬂamma-
tion [13]. The effect of these parameters on the inﬂammation and
the cumulative effect of several risk factors have not been sufﬁ-
ciently explored [14].
The aim of this study was to evaluate the associations
between C3 and anthropometric measurements, body compo-




In this study, 157 healthy subjects 18 to 35 y old were recruited to participate
(91 women and 66 men, 23.3  3.5 y old, BMI 22.0  2.9 kg/m2). The initial
enrollment screening included evaluations to exclude subjects with evidence of
any disease related to chronic inﬂammation, oxidative stress, hydric unbalance,
and changes in body composition, nutrient absorption, or metabolism. Other
exclusion criteria were drug or nutritional treatments that affect energy balance,
dietary intake, lipid proﬁle, insulin levels, and glucose metabolism; contraceptive
use up to 2 mo before participation in this study; and recent diets designed for
weight loss or unstable weight in the previous 6 mo. In accordance with the
principals of the Declaration of Helsinki, each participant provided a written
informed consent to participate after a clear explanation of the study protocol.
The study was approved by the committee of ethics in research with humans of
Vic¸osa University, Minas Gerais State, Brazil (ofﬁcial reference no. 009/2006).
Anthropometric, body composition, and blood pressure assessments
Body weight was measured to the nearest 0.1 kg using an electronic micro-
digital scale balance (model TBF-300A, Tanita, Tokyo, Japan). Height was
measured with a stadiometer (model 206, Seca, Hamburg, Germany) to the
nearest 0.1 cm [15]. From those measurements, the BMI was calculated [16].
Thereafter, the BMI was calculated and used to categorize the underweight/
normal weight (BMI 24.9 kg/m2) and overweight/obesity (BMI 25.0 kg/m2) of
the volunteers according to the World Health Organization [16]. The WC, hip
circumference (HC) [16], and arm circumference [17] were measured with an
inelastic and ﬂexible tape to the nearest 0.1 cm. The waist-to-hip ratio was also
calculated [16]. Triceps, biceps, subscapular, and suprailiac skinfold thicknesses
(STs) were measured to the nearest 1 mm using a skinfold caliper (Lange caliper,
Cambridge Scientiﬁc Industries, Inc., Cambridge, MD, USA) according to a previ-
ously described protocol [18]. The sum of four STs was calculated, and the
percentage of body fat (%BF) was estimated according to equations published
previously [19,20]. Also, the arm fat area (AFA; square centimeters) and adipo-
se–muscle arm index (A-MAI) [17] were calculated. Measurements of body fat
mass (BFM; kilograms), fat-free mass (kilograms), and %BF were determined
using a body composition analyzer (model 310, Biodynamics, Seattle, WA, USA)
[21]. Systolic and diastolic blood pressures were measured by a mercury
sphygmomanometer (BIC, S~ao Paulo, Brazil) to the nearest 2 mmHg, as described
previously [22].
Analyses of biological samples
Blood samples were drawn by vein puncture after a 12-h overnight fast. The
ethylenediaminetetra-acetic acid plasma and serum samples were separated
fromwhole blood by centrifugation at 2465  g at 5C for 15 min (model 5804R,
Eppendorf AG, Hamburg, Germany) and were immediately stored at 80C until
the assay. Serum C3, glucose, total cholesterol, triacylglycerols, high-density
lipoprotein cholesterol (HDL-C), total proteins, uric acid, and ceruloplasmin
concentrations (milligrams per deciliter) were assessed by automatized colori-
metric or turbidimetric assays (model BS-200, Shenzhen Mindray Bio-medical
Electronics Co., Nanshan, China) with speciﬁc commercially available kits
(Bioclin, Quibasa, Minas Gerais, Brazil). Low-density lipoprotein cholesterol
(LDL-C) data were calculated by the Friedewald equation, as described elsewhere
[23]. Then, the ratio of total cholesterol to HDL-C (atherogenic index) was
calculated [24]. Plasma insulin concentrations (sensitivity 2 mU/mL) were
measured by an enzyme-linked immunosorbent assay kit using a speciﬁc
monoclonal antibody, 4E6, as described by the supplier (Mercodia, Uppsala,
Sweden). Also, to determine sensitivity to insulin, the homeostasis model
assessment of IR (HOMA-IR) was calculated [25].Lifestyle assessments
For non-dietary covariates, a questionnaire on lifestyle habits was used to
collect lifestyle information such as smoking (number of smokers and non-
smokers), regularly practiced sports activities (yes or no), and pattern of phys-
ical activity (hours per week). To quantify the amount (Pattern) of physical
activity, a metabolic equivalent index (MET) was calculated to denote a multiple
of the restingmetabolic rate for each physical activity performed during theweek
and weekend. These values were then converted into METs per hour [26].
Statistical methods
The Shapiro–Wilk normality test was used to determine the variable
distribution. Comparisons between groups were made by a Wilcoxon–Mann–
Whitney U test. Spearman correlation coefﬁcients were used to screen for
statistical associations between C3 concentrations (dependent variable) and the
variables of interest. A multiple regression model was used to identify possible
predictors of C3 using the technique of indirect elimination (backward) for the
selection of variables and including the variables gender, smoking, and physical
activity (qualitative variables) as indicator variables. Then, these analyses were
performed for a subgroup without IR. For these analyses, IR was considered
when the HOMA-IR was p90 (HOMA-IR  3.79). Results are presented as
median (interquartile range). Multiple regression coefﬁcients (b) were
described using 95% conﬁdence intervals. P < 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using SAS 9.0 (SAS Institute,
Cary, NC, USA).
Results
Anthropometric, biochemical data, and lifestyle features
assessments
The general characteristics for age, anthropometric and
biochemical data, body composition, data on systolic and dia-
stolic blood pressures, and METs are presented in Table 1. The
anthropometric data showed that BFM (bioelectrical impedance
analysis [BIA]) and WC were signiﬁcantly greater in women and
men, respectively (P < 0.05; Table 2).
According to nutritional status, the total sample of volunteers
consisted of 86.6% (n ¼ 136) with underweight/normal weight
and 13.4% (n ¼ 21) with overweight or obesity according to the
World Health Organization (WHO) categorization [16]. Except for
age, all anthropometric and body composition measurements
were signiﬁcantly higher in overweight/obese volunteers (P <
0.05). For the sample divided by nutritional status, concentra-
tions of C3, glucose, insulin, and uric acid, values of HOMA-IR,
and the atherogenic index were higher in the overweight or
obese group compared with the low-weight/normal-weight
group (P < 0.05; data not shown).
For the data indicating the lifestyle of volunteers, 10.8% and
89.2% of the volunteers were smokers and non-smokers,
respectively, (n ¼ 15/124) and 71.95% and 28.05% of the volun-
teers participated or did not participate regularly in sports
activities, respectively (n ¼ 100/39). Only 88.53% of the volun-
teers returned the lifestyle habits questionnaire (n ¼ 139).
Correlations between C3 and adiposity indicators, IR, and MS
The correlations between C3 and age, anthropometric and
biochemical data, body composition, data on systolic and dia-
stolic blood pressures, and MET are presented in Table 3.
For the total volunteer sample, the correlations between C3
and anthropometric measurements and body composition
demonstrated a direct and signiﬁcant association between C3
and BMI, tricipital ST, bicipital ST, subscapular ST, suprailiac ST,
the sum of the four STs, %BF (ST), BFM (BIA), %BF (BIA), AFA, A-
MAI, WC, and HC (P < 0.05). The correlation between C3 and
biochemical characteristics of the volunteers demonstrated
Table 1
General, anthropometric, biochemical, and lifestyle data of volunteers (n ¼ 157)
Mean  SD CI Median IQR P
C3 (mg/dL) 112.52  23.56 20–171 114 102–128 <0.0012
Age (y) 23.3  3.5 18–35 23 21–25 <0.0001
BMI (kg/m2) 22.08  2.99 16.7–34.9 21.5 20.3–23.3 <0.0001
Tricipital ST (mm) 18.13  6.88 5.0–41.0 18.0 13.0–22.5 0.0185
Bicipital ST (mm) 7.27  3.80 2.0–23.0 7.0 4.0–9.0 <0.0001
Subscapular ST (mm) 17.71  7.31 7.0–43.0 15.5 12.5–20.5 <0.0001
Suprailiac ST (mm) 18.03  8.95 4.5–48.0 18.03 11.0–22.5 <0.0001
Sum of 4 STs (mm) 61.15  23.85 21.5–148.0 57.0 42.3–75.0 <0.0001
%BF (ST) 25.33  7.50 8.1–42.3 26.5 19.0–31.2 0.0021
BFM (kg) (BIA) 14.79  5.18 4.9–41.1 13.80 11.1–17.4 <0.0001
FFM (kg) (BIA) 47.57  10.12 20.6–72.0 45.30 39.5–55.9 0.0003
%BF (BIA) 23.57  6.48 9.4–38.3 23.50 18.7–28.25 0.1336
AC (cm) 28.13  3.71 21.0–39.5 27.50 25.5–30.0 0.0006
AFA (cm2) 22.75  9.15 5.93–60.6 22.2 15.97–27.4 <0.0001
A-MAI 0.62  0.31 0.12–1.48 0.58 0.38–0.81 0.0003
WC (cm) 78.0  8.51 60.0–100.0 77.0 71.5–83.0 <0.0001
HC (cm) 95.47  6.72 69.0–114.5 95.5 91.0–100.0 0.2554
WHR 0.81  0.06 0.65–1.01 0.82 0.78–0.85 0.3008
Systolic blood pressure (mmHg) 109.4  0.93 90–140 110 100–120 <0.0001
Diastolic blood pressure (mmHg) 73.3  0.66 60–90 70 70–80 <0.0001
Glucose (mg/dL) 90.31  6.26 72–106 90 87–94 0.31
Insulin (mU/mL) 10.10  5.63 0.49–45.46 9.50 6.55–12.95 <0.001
HOMA-IR index 2.26  1.27 0.11–9.08 2.14 1.43–2.86 <0.001
Total cholesterol (mg/dL) 159.66  31.22 100–268 157 140–177 <0.0001
Triacylglycerols (mg/dL) 100.15  44.62 34–373 91 69–121 <0.0001
HDL-C (mg/dL)* 46  10,46 21–71 45 38–53 <0.003
LDL-C (mg/dL) 95.68  26.93 41.8–181.6 91.20 78.4–109.6 <0.001
Atherogenic index* 3.56  0.80 2.21–8.24 3.47 3.06–4.0 <0.0001
Total proteins (mg/dL) 6.74  0.38 5.9–7.8 6.8 6.5–7.0 0.2097
Uric acid (mg/dL) 3.56  1.06 1.1–6.5 3.4 2.8–4.2 0.1370
Ceruloplasmin (mg/dL) 37.21  8.36 21.4–56.2 34.8 31.1–43.1 <0.001
METy 76.93  23.60 31.3–197.7 72.25 60.80–88.60 <0.0001
AC, arm circumference; AFA, arm fat area; A-MAI, adipose–muscle arm index; %BF, percentage of body fat; BFM, body fat mass; BIA, bioelectrical impedance analysis;
BMI, bodymass index; C3, complement factor-3; CI, conﬁdence interval; FFM, fat-free mass; HC, hip circumference; HDL-C, high-density lipoprotein cholesterol; HOMA-
IR, homeostasis model assessment of insulin resistance; IQR, interquartile range (quartiles 1–3); LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent
index; ST, skinfold thickness; WC, waist circumference; WHR, waist-to-hip ratio
Test of normality: Shapiro-Wilk, P < 0.05
* For 150 volunteers.
y For 139 volunteers.
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HOMA-IR, total cholesterol, triacylglycerols, the atherogenic
index, and ceruloplasmin (P < 0.05). There was no correlation
between C3 and age and blood pressure (P > 0.05).
For the subgroup without IR, the correlations between C3 and
anthropometric measurements and body composition demon-
strated a direct and signiﬁcant association between C3 and tri-
cipital ST, bicipital ST, subscapular ST, suprailiac ST, the sum of
the four STs, %BF (ST), BFM (BIA), %BF (BIA), AFA, A-MAI, WC, and
HC (P < 0.05). The correlation between C3 and the biochemical
characteristics of the volunteers demonstrated a direct and
signiﬁcant association between C3 and insulin, HOMA-IR, total
cholesterol, triacylglycerols, LDL-C, the atherogenic index, and
ceruloplasmin (P < 0.05). There was no correlation between C3
and age and blood pressure (P > 0.05).
Possible predictive factors for C3 concentrations
Based on the relation between the biochemical and anthro-
pometric data, body composition and lifestyle indicators with C3,
we performed a multiple linear regression analysis to assess the
possible predictors of C3 concentrations.
For the total volunteer sample, with regard to the biochemical
data, the model that best explained the variation (20.48%) in C3
concentrationswas deﬁned by the following regression equation:
C3 ¼ 85.20 þ 0.13  triacylglycerols  0.41  HDL-C þ 0.87 
ceruloplasmin (P< 0.05; Table 4, model 1).Whenwe inserted theindicator variables gender, smoking, and physical activity, the
model explained 13.79% of the C3 concentrations andwas deﬁned
by the following regression equation: C3 ¼ 92.49 þ 0.19  tri-
acylglycerols (P < 0.05; Table 4, model 2; Fig. 1). In this model,
there were no signiﬁcant effects of gender, smoking, or physical
activity (PA) (P > 0.05).
For anthropometric data and body composition, blood pres-
sure, and MET, the model that best explained the variation
(6.21%) in C3 concentration was deﬁned by the following
regression equation: C3¼ 94.98þ 1.18 BFM determined by BIA
(P < 0.05; Table 4, model 3). When we inserted the indicator
variables gender, smoking, and physical activity, the model
remained unchanged (P < 0.05; Table 4, model 3; Fig. 2),
and there were no signiﬁcant effects of gender, smoking, or PA
(P > 0.05). All models were adjusted for age.
For the subgroup without IR, with respect to the biochemical
data, the model that best explained the variation (18.71%) in C3
concentrationswas deﬁned by the following regression equation:
C3 ¼ 58.68 þ 0.16  triacylglycerols þ 3.81  uric acid þ 0.61 
ceruloplasmin (P< 0.05; Table 5, model 1).Whenwe inserted the
indicator variables gender, smoking, and physical activity, the
model explained 14.23% of the C3 concentrations andwas deﬁned
by the following regression equation: C3 ¼ 88.64 þ 0.22  tri-
acylglycerols (P < 0.05; Table 5, model 2). In this model, there
were no signiﬁcant effects of gender, smoking, or PA (P > 0.05).
For anthropometric data and body composition, blood pres-
sure, and MET, the model that best explained the variation
Table 2
General, anthropometric, biochemical, and lifestyle data of volunteers by gender (n ¼ 157)
Women (n ¼ 91) Men (n ¼ 66) P
Median IQR Median IQR
C3 (mg/dL) 115 101–131 110 102–123 0.2433
Age (y) 23 21–25 22 20–25 0.0309
BMI (kg/m2) 21.1 19.7–23.0 22.45 21.0–24.4 <0.0016
Tricipital ST (mm) 21.0 17.0–24.5 14.25 10.0–17.5 <0.0001
Bicipital ST (mm) 8.0 6.5–11.0 4.0 3.0–6.0 <0.0001
Subscapular ST (mm) 16.7 13.0–22.0 15.0 11.0–18.5 0.0606
Suprailiac ST (mm) 20.0 15.0–24.0 12.0 9.0–17.0 <0.0001
Sum of 4 STs (mm) 66.0 52.0–80.5 46.7 35.0–57.0 <0.0001
%BF (ST) 30.2 26.5–33.1 17.7 14.7–20.1 <0.0001
BFM (kg) (BIA) 15.1 12.8–17.6 12.05 9.8–15.2 <0.0001
FFM (kg) (BIA 40.7 36.9–44.0 57.8 52.3–62.2 <0.0001
%BF (BIA) 26.8 23.8–31.0 17.65 15.0–20.7 <0.0001
AC (cm) 26.5 24.5–28.0 29.7 28.0–33.0 <0.0001
AFA (cm2) 23.59 18.31–30.09 18.57 13.9–24.6 0.0007
A-MAI 0.75 0.59–0.97 0.38 0.26–0.48 <0.0001
WC (cm) 76.5 69.5–82.5 79.25 74.5–86.0 0.0103
HC (cm) 96.0 91.5–100.0 94.5 90.0–99.0 0.1265
WHR 0.80 0.75–0.84 0.84 0.81–0.89 <0.0001
Systolic blood pressure (mmHg) 110 100–110 110 110–120 <0.0001
Diastolic blood pressure (mmHg) 70 70–80 80 70–80 0.0001
Glucose (mg/dL) 88 85–92 92 88–97 0.0002
Insulin (mU/mL) 10.16 6.88–13.27 8.64 6.06–12.04 0.2687
HOMA-IR index 2.21 1.44–2.97 1.96 1.37–2.77 0.4837
Total cholesterol (mg/dL) 165 145–187 146 134–160 <0.0001
Triacylglycerols (mg/dL) 99 79–127 81.5 67–101 0.0038
HDL-C (mg/dL)* 52 45–57 38 36–43 <0.0001
LDL-C (mg/dL) 98.2 77.8–114.4 87.7 78.4–102.8 0.0751
Atherogenic index* 3.29 2.83–3.76 3.73 3.39–4.17 <0.0001
Total proteins (mg/dL) 6.7 6.4–7.0 6.8 6.6–7.0 0.0290
Uric acid (mg/dL) 3.0 2.4–3.5 4.15 3.6–4.8 <0.0001
Ceruloplasmin (mg/dL) 41 33.0–48.5 31.6 29.2–34.4 <0.0001
METy 76 60.3–89.7 71.7 62.3–84.3 0.1572
AC, arm circumference; AFA, arm fat area; A-MAI, adipose–muscle arm index; %BF, percentage of body fat; BFM, body fat mass; BIA, bioelectrical impedance analysis;
BMI, body mass index; C3, complement factor-3; FFM, fat-free mass; HC, hip circumference; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model
assessment of insulin resistance; IQR, interquartile range (quartiles 1–3); LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent index; ST, skinfold
thickness; WC, waist circumference; WHR, waist-to-hip ratio
For differences between groups: Wilcoxon–Mann–Whitney U test, P < 0.05
* For 85 women and 65 men.
y For 78 women and 61 men.
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regression equation: C3¼ 95.70þ 1.05 BFM determined by BIA
(P < 0.05; Table 5, model 3). When we inserted the indicator
variables gender, smoking, and physical activity, the model
remained unchanged (P< 0.05; Table 5, model 3), and therewere
no signiﬁcant effects of gender, smoking, or PA (P > 0.05). All
models were adjusted for age.
Discussion
In this study, after the correlation analysis, there was a direct
and signiﬁcant association of C3 with BMI (all volunteers) and
adiposity measurements, including the tricipital, bicipital, sub-
scapular, and suprailiac STs, the sum of the four STs, %BF (ST),
BFM (BIA), %BF (BIA), AFA, A-MAI, WC, and HC (P < 0.05).
Nevertheless, when the analysis was performed by multiple
linear regression to assess the possible predictors of C3
concentrations, for the total volunteer sample, BFM (BIA)
explained 6.21% of the variation in C3 concentration. For this
sample of volunteers, for each 1-kg increase in BFM (BIA), the C3
concentrations increased 1.18 mg/dL (P< 0.05). For the subgroup
without IR, BFM (BIA) explained 5.11% of the variation in C3
concentration. For this subgroup of volunteers, for each 1-kg
increase in BFM (BIA), C3 concentrations increased 1.05 mg/dL
(P < 0.05). Nevertheless, BFM (BIA) explained variations in C3regardless of gender, smoking, and physical activity. In this
context, and in accordance with our results, inﬂammation can
occur in individuals independently of BMI but dependently and
proportionally of BFM. This fact demonstrates that volunteers
classiﬁed as being underweight/normal weight [16] can also
present excesses of BFM and IR.
Complement factor-3 is a protein of liver inﬂammation [5],
but activated macrophages and adipose tissue also synthesize C3
[3,6], thus explaining the relation between C3 and adiposity. In
addition, the fragment of C3 (C3adesArg), also known as
acylation-stimulating protein (ASP), is a hormone produced by
adipocytes as a result of the interaction of C3, factor B, and
adipsin (factor D) [27]. ASP stimulates glucose transport through
the membrane and the synthesis of triacylglycerols in adipo-
cytes, an action independent and additional to that exerted by
insulin [28]. Thus, C3 and ASP are increased in individuals with
excess adiposity and with obesity [27], conﬁrming the C3 results
found in this study.
The relation between adiposity, particularly central obesity
(visceral), and the increased production of hepatic inﬂammatory
proteins has been described by some researchers [29,30].
The expansion of adipose tissue leads to adipocyte hypertrophy
and hyperplasia, and these large adipocytes decrease the local
supply of oxygen, leading to autonomous cell hypoxia with the
resultant activation of cellular stress pathways (oxidative or
Table 4
Multiple linear regression models to predict possible complement factor-3
concentrations (n ¼ 157)
Coefﬁcient b  SD P
Model 1*
Intercept 85.20  8.79 <0.0001
Triacylglycerols (mg/dL) 0.13  0.03 0.0007
HDL-C (mg/dL) 0.41  0.18 0.0300
Ceruloplasmin (mg/dL) 0.87  0.25 0.0006
Model 2y
Intercept 92.49  4.30 <0.0001
Triacylglycerols (mg/dL) 0.19  0.03 <0.0001
Model 3z
Intercept 94.98  5.51 <0.0001
BFM (kg) (BIA) 1.18  0.35 0.0010
BFM, body fat mass; BIA, bioelectrical impedance analysis; HDL-C, high-density
lipoprotein cholesterol
* Variables included were age, glucose, insulin, homeostasis model assessment
of insulin resistance index, total cholesterol, triacylglycerols, HDL-C, total
proteins, uric acid, and ceruloplasmin (r2 ¼ 0.2048, P < 0.0001).
y Adjusted for the variables gender, smoking, and physical activity. Variables
included were age, glucose, insulin, homeostasis model assessment of insulin
resistance index, total cholesterol, triacylglycerols, HDL-C, total proteins, uric
acid and ceruloplasmin (r2 ¼ 0.1379, P < 0.0001).
z With and without adjustment for the variables gender, smoking, and phys-
ical activity. Variables included were age, body mass index; tricipital, bicipital,
subscapular, and suprailiac skinfold thicknesses; fat-free mass (BIA); BFM (BIA),
percentage of body fat (BIA); arm circumference, waist circumference; hip
circumference; systolic blood pressure; diastolic blood pressure; and the meta-
bolic equivalent index (r2 ¼ 0.0621, P ¼ 0.0010).
Fig. 1. Independent association between triacylglycerol concentration and C3
(n ¼ 157). C3, complement factor-3.
Table 3
Correlations between complement factor-3 and general, anthropometric,




IR* (n ¼ 139)
r P r P
Age (y) 0.00770 0.9237 0.00391 0.9636
BMI (kg/m2) 0.23417 0.0032 0.16546 0.0516
Tricipital ST (mm) 0.27422 0.0005 0.24573 0.0035
Bicipital ST (mm) 0.23631 0.0029 0.19630 0.0206
Subscapular ST (mm) 0.28093 0.0004 0.23860 0.0047
Suprailiac ST (mm) 0.25729 0.0011 0.22538 0.0076
Sum of 4 STs (mm) 0.31070 <0.0001 0.27020 0.0013
%BF (ST) 0.26380 0.0008 0.23968 0.0045
BFM (kg) (BIA) 0.33407 <0.0001 0.29898 0.0003
FFM (kg) (BIA 0.05912 0.4620 0.02860 0.7382
%BF (BIA) 0.26873 0.0007 0.28288 0.0007
AC (cm) 0.10047 0.2106 0.5464 0.5229
AFA (cm2) 0.28191 0.0003 0.24103 0.0043
A-MAI 0.26581 0.0008 0.24769 0.0033
WC (cm) 0.21266 0.0075 0.19529 0.0212
HC (cm) 0.25132 0.0015 0.22443 0.0079
WHR 0.07694 0.3381 0.07507 0.3798
Systolic blood pressure (mmHg) 0.07993 0.3197 0.03493 0.6831
Diastolic blood pressure (mmHg) 0.2969 0.7120 0.00689 0.9358
Glucose (mg/dL) 0.01891 0.8141 0.05154 0.5468
Insulin (mU/mL) 0.26152 0.0009 0.19175 0.0237
HOMA-IR index 0.24831 0.0017 0.17403 0.0405
Total cholesterol (mg/dL) 0.23335 0.0033 0.27754 0.0009
Triacylglycerols (mg/dL) 0.38435 <0.0001 0.35954 <0.0001
HDL-C (mg/dL)y 0.01804 0.8266 0.06555 0.4552
LDL-C (mg/dL) 0.12770 0.1110 0.17879 0.0352
Atherogenic indexy 0.19622 0.0161 0.17229 0.0482
Total proteins (mg/dL) 0.14448 0.0710 0.16650 0.0501
Uric acid (mg/dL) 0.10596 0.1866 0.8308 0.3309
Ceruloplasmin (mg/dL) 0.37139 <0.0001 0.38127 <0.0001
METz 0.02036 0.8126 0.02771 0.7629
AC, arm circumference; AFA, arm fat area; A-MAI, adipose–muscle arm index; %
BF, percentage of body fat; BFM, body fat mass; BIA, bioelectrical impedance
analysis; BMI, body mass index; FFM, fat-free mass; HC, hip circumference; HDL-
C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assess-
ment of insulin resistance; IR, insulin resistance; LDL-C, low-density lipoprotein
cholesterol; MET, metabolic equivalent index; ST, skinfold thickness; WC, waist
circumference; WHR, waist-to-hip ratio
Test of correlation: Spearman, P < 0.05
* IR was considered when the HOMA-IR was p90 (HOMA-IR  3.79).
For total volunteers: y n ¼ 150, z n ¼ 139.
For the subgroup without IR: y n ¼ 132, z n ¼ 121.
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(autocrine effect) and the release of cytokines and other proin-
ﬂammatory signals. Like resistin, leptin and adiponectin, which
are secreted by adipocytes, adipokines may also affect inﬂam-
mation and IR. As part of the chronic inﬂammatory process
and with low intensity, locally secreted chemokines attract
proinﬂammatory macrophages to adipose tissue that form
a crown-shaped structure around the large, dead, and/or inﬁrm
adipocytes. Then, these macrophages stimulate the release of
cytokines that have yet to activate inﬂammatory pathways in
adipocytes and other tissues, such as hepatocytes (autocrine and
paracrine effect), aggravated inﬂammation, and IR [29,30]. Thus,
hepatic inﬂammation can occur in individuals with an excess of
adiposity because the activation of inﬂammatory pathways may
be the result of steatosis and/or increased airway responses to
stress in hepatocytes. This can result in the inﬂammation of
autonomous hepatocytes (autocrine effect). The Kupffer cells
(liver cells resembling macrophages) may also become activated,
thus stimulating the local release of cytokines that further
aggravate hepatic inﬂammation and IR. In addition, caloric
surplus and an excess of adiposity are frequently accompanied by
increased concentrations of circulating and tissue free fatty acids,and these can directly activate proinﬂammatory responses in
vascular endothelial cells, adipocytes, and myeloid cells [29,30].
The result of these physiologic events induced by an excess of
adiposity is the development of systemic inﬂammation [30].
Thus, it seems that the process is bidirectional and additive; C3 is
produced by fat tissue, and its concentration can increase
because of a larger supply of BF; C3 is still a liver protein of
systemic inﬂammation, and its concentration can increase with
greater inﬂammation independent of hepatocytes (steatosis
from cellular hypoxia generated by an excess of BFM).
In regard to the biochemical data, there was a direct and
signiﬁcant association of C3 with total cholesterol, triacyl-
glycerols, LDL-C (subgroup without IR), the atherogenic index,
insulin, HOMA-IR, and ceruloplasmin (P < 0.05). When we
applied multiple linear regression analysis to assess the possible
predictors of C3, for the total volunteer sample, triacylglycerols,
HDL-C, and ceruloplasmin explained 20.48% of the variation in
C3 concentration (P < 0.05). For this sample of volunteers, for
each increase of 1.0 mg/dL in triacylglycerols and 1.0 mg/dL in
ceruloplasmin, there were 0.13- and 0.87-mg/dL increases in C3
Fig. 2. Independent association between body fat mass and C3 (n ¼ 157). BIA,
bioelectrical impedance analysis; C3, complement factor-3.
A. C. P. Volp et al. / Nutrition 28 (2012) 544–550 549concentrations, respectively. Similarly, each 1.0-mg/dL decrease
in HDL-C correlated with a 0.41-mg/dL increase in C3 concen-
tration (P < 0.05). For the subgroup without IR, triacylglycerols,
uric acid, and ceruloplasmin explained 18.71% of the variation in
C3 concentration (P < 0.05). For this sample of volunteers, for
each increase of 1.0 mg/dL in triacylglycerols, 1.0 mg/dL in uric
acid, and 1.0 mg/dL in ceruloplasmin, there were increases
of 0.16, 3.81, and 0.61 mg/dL in C3 concentrations, respectively
(P< 0.05). Nevertheless, triacylglycerols explained the variations
in C3 regardless of gender, smoking, and physical activity.
Studies have conﬁrmed that C3 is correlated with fasting
insulin [31], IR [32], and total cholesterol [31,33]. However, C3
concentrations are higher in obese non-diabetics and type 2
diabetics than in healthy men, whereas C3 concentrations are
similar between obese non-diabetics and type 2 diabetics and
between type 1 diabetics and lean, healthy young men. In the
same study, C3 concentrations did not differ between healthy
men and young adults [34]. It is noteworthy that in this study
there was no correlation between C3 and age, and all models ofTable 5
Multiple linear regression models to predict possible complement factor-3
concentrations in volunteers without insulin resistance* (n ¼ 139)
Coefﬁcient b  SD P
Model 1y
Intercept 58.68  12.03 <0.0001
Triacylglycerols (mg/dL) 0.16  0.05 0.0026
Uric acid (mg/dL) 3.81  1.82 0.0383
Ceruloplasmin (mg/dL) 0.61  0.26 0.0196
Model 2z
Intercept 88.64  4.99 <0.0001
Triacylglycerols (mg/dL) 0.22  0.04 <0.0001
Model 3x
Intercept 95.70  5.88 <0.0001
BFM (kg) (BIA) 1.05  0.38 0.0074
BFM, body fat mass; BIA, bioelectrical impedance analysis
* Insulin resistance was considered when the homeostasis model assessment
of insulin resistance index was p90 (homeostasis model assessment of insulin
resistance index 3.79).
y Variables included were age, glucose, insulin, the homeostasis model
assessment of insulin resistance index, total cholesterol, triacylglycerols, high-
density lipoprotein cholesterol, total proteins, uric acid, and ceruloplasmin
(r2 ¼ 0.1871, P < 0.0001).
z Adjusted for the variables gender, smoking, and physical activity. Variables
included were age, glucose, insulin, the homeostasis model assessment of insulin
resistance index, total cholesterol, triacylglycerols, high-density lipoprotein
cholesterol, total proteins, uric acid, and ceruloplasmin (r2¼ 0.1423, P< 0.0001).
x With and without adjustment for the variables gender, smoking, and phys-
ical activity. Variables included were age, body mass index; tricipital, bicipital,
subscapular, and suprailiac skinfold thicknesses; fat-free mass (BIA); BFM (BIA);
percentage of body fat (BIA); arm circumference; waist circumference; hip
circumference; systolic blood pressure; diastolic blood pressure; and the meta-
bolic equivalent index (r2 ¼ 0.0511, P ¼ 0.0074).multiple linear regression analysis remained unchanged when
adjusted for age. Although the age of the volunteers was
restricted to young adults (18–35 y), this result is consistent with
a study that showed that C3 was not modiﬁed by age [34].
The positive correlations between C3 concentrations and
triacylglycerols is consistent with others studies [11,12]. The
relation between C3 and biochemical measurements can be
explained by the products of metabolism, i.e., ASP is a hormone
also produced by adipocytes as a result of the interaction of C3,
factor B, and adipsin (factor D) [27]. The events stimulate glucose
transport through membranes and increase the synthesis of
triacylglycerols in adipocytes, an action independent and addi-
tional to that exerted by insulin [28]. Just as for C3, ASP
concentrations are increased in individuals with excess adiposity
and obesity, diabetes, and cardiovascular disease [27]. Although
the receptors and signaling mechanisms mediated by ASP are
still unknown, there is evidence that ASP is involved in the
activation of glucose transport and the stimulation of its
absorption. As a result, ASP increases the re-esteriﬁcation of fatty
acids, the efﬁciency of triacylglycerol synthesis in adipocytes
through the paracrine and autocrine effects, and the activation of
diacylglycerol acyl-transferase and inhibits hormone-sensitive
lipase activity and lipolysis [27,35]. The result of the action of
ASP is a rapid postprandial lipid clearance. Therefore, the C3/ASP
system has been proposed to be a regulator of fatty acid
metabolism in adipose tissue [36]. Nonetheless, it is noteworthy
that C3 is an inﬂammatory biomarker; thus, the direct associa-
tion between C3 and ceruloplasmin (a glycoprotein family
member of inﬂammation-sensitive proteins) [37,38] in the
present study is expected.
Thus, inﬂammation assessed by C3 appears to bemodulated by
anthropometry and body composition and by biochemical factors,
and MS components seem to be good indicators of subclinical
inﬂammation. These results are conﬁrmed by the scientiﬁc litera-
ture. One study demonstrated that C3 was independently associ-
ated with measurements of adiposity and triacylglycerols [11]. In
our study, in a model with all covariates added, measurements of
adiposity (BFM) and triacylglycerols also were independent
possible predictors of C3 concentrations. In fact, C3 is partly
secreted by adipocytes [6] and its fragment, ASP, is a potent
simulatorof glucose transport and triacylglycerol synthesis [27,35].
Other investigators have shown that a high C3 concentration
is associated with cardiovascular diseases [39], WC, and high
triacylglycerol concentrations in the fasting and postprandial
states, proposing that it is a coronary risk factor [11], a risk factor
for the development of diabetes [10] and obesity [34], and
a useful marker for identifying people with MS [12].
These results are clinically important because the association
between C3 and the development of atherosclerosis (myocardial
infarction) can occur from the following mechanisms: 1)
vulnerable plaques rich in macrophages and lipid may represent
a source of the direct or indirect production of C3, which can thus
be a marker for the presence of these plaques; 2) some C3
fragments and other cytokines [31,40] are associated with MS
and a pro-atherogenic state, including IR and C3 (with other
cytokines), and may play a causal role; and 3) these mechanisms
can coexist in a circular process in which vulnerable plaques
producing cytokines and C3 can trigger MS, which then
promotes the growth of existing plaques and the formation of
new plaques [40].
Our study had certain limitations. Because the nature of this
study was cross-sectional, we cannot prove that the reported
associations are causal because residual confounding may have
affected the observed associations, although we controlled for
A. C. P. Volp et al. / Nutrition 28 (2012) 544–550550potential covariates. However, we controlled for the more
important known factors that affect inﬂammation. Although the
sample size was adequate from the standpoint of the initial
association discovery, further replication in independent and
larger samples would be convenient for a future translational
application at a population level.
In summary, the present study analyzed the association
between C3 and anthropometric measurements and body
composition, biochemical parameters, and lifestyle in apparently
healthy young adults. It demonstrated also that C3 correlated
with measurements of adiposity and that BFM was a possible
predictive of C3 concentrations. C3 was correlated with the
following biochemical measurements: insulin, total cholesterol,
triacylglycerols, ceruloplasmin, HOMA-IR, and the atherogenic
index. Moreover, the possible predictors of C3 were tri-
acylglycerols and ceruloplasmin. Nevertheless, we demonstrated
an independent role for triacylglycerols, a component of MS, and
BFM as possible predictors of C3 in young healthy adults.
Conclusion
This study contributes to a better understanding of the
associations between C3 and the risk factors for the occurrence
of MS at an early stage. Triacylglycerols and BFM were possible
independent predictors of C3 in apparently healthy young Bra-
zilian adults.
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